News
CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
The recently hosted CPhI & P-MEC China 2020 – organized by Informa Markets and CCCMHPIE and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. – attracted a remarkable 46,157 visits of professional pharma visitors, including 5,105 international...
Drug Research
ConserV Bioscience and Lawrence Livermore National Laboratory to Collaborate on Development of Broad-spectrum Coronavirus Vaccine
ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases and Lawrence Livermore National Laboratory (“LLNL”) have agreed to collaborate on the development of a broad-spectrum coronavirus vaccine.
This collaboration...
News
Aruvant Chooses Lonza to Manufacture ARU-1801, a Potentially Curative Treatment for Sickle Cell Disease, for Pivotal Trial
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). Aruvant has chosen Lonza to help develop...
News
ViGeneron inks research pact with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
ViGeneron GmbH, a gene therapy company, announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited, for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent...
Drug Research
Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa
Novartis and GSK announced the launch of a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics.
The Project Africa Genomic Research Approach...
News
NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms
“NextPharma is an established and well-respected company, with extensive experience in oral and topical finished dosage forms. As such, it is the ideal buyer given the technologies available at the Ploermel and Edinburgh sites. We are confident that the...
Clinical Trials
Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio
Intravacc, a world leader in translational research and development of vaccines, announced that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less than 36 months, has entered into a first in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















